Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study BioSpaceA single 1-mg/kg dose of Eli Lilly's base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) BioSpace A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. Cardiovascular Read full story Post navigation Previous: Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRCNext: Arthrosi drug trial in gout delivers for new owner Sobi Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026